JP6783652B2 - 抗原特異的免疫原性を低減するための組成物及び方法 - Google Patents

抗原特異的免疫原性を低減するための組成物及び方法 Download PDF

Info

Publication number
JP6783652B2
JP6783652B2 JP2016516601A JP2016516601A JP6783652B2 JP 6783652 B2 JP6783652 B2 JP 6783652B2 JP 2016516601 A JP2016516601 A JP 2016516601A JP 2016516601 A JP2016516601 A JP 2016516601A JP 6783652 B2 JP6783652 B2 JP 6783652B2
Authority
JP
Japan
Prior art keywords
opls
fviii
antigen
administered
gaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016516601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531853A (ja
JP2016531853A5 (enExample
Inventor
バルー‐アイヤー，サティ
コスロスキ，マシュー，ピー．
シェティ，クリティカ，アルン
シュナイダー，ジェニファー，リー
ファタラー，アナス
Original Assignee
ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク, ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク filed Critical ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Publication of JP2016531853A publication Critical patent/JP2016531853A/ja
Publication of JP2016531853A5 publication Critical patent/JP2016531853A5/ja
Application granted granted Critical
Publication of JP6783652B2 publication Critical patent/JP6783652B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016516601A 2013-09-24 2014-09-24 抗原特異的免疫原性を低減するための組成物及び方法 Active JP6783652B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881857P 2013-09-24 2013-09-24
US61/881,857 2013-09-24
PCT/US2014/057234 WO2015048145A1 (en) 2013-09-24 2014-09-24 Compositions and methods for reducing antigen-specific immunogenicity

Publications (3)

Publication Number Publication Date
JP2016531853A JP2016531853A (ja) 2016-10-13
JP2016531853A5 JP2016531853A5 (enExample) 2017-09-28
JP6783652B2 true JP6783652B2 (ja) 2020-11-11

Family

ID=52744422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516601A Active JP6783652B2 (ja) 2013-09-24 2014-09-24 抗原特異的免疫原性を低減するための組成物及び方法

Country Status (6)

Country Link
US (1) US20160243220A1 (enExample)
EP (1) EP3049103B1 (enExample)
JP (1) JP6783652B2 (enExample)
CN (1) CN105992591A (enExample)
ES (1) ES2807550T3 (enExample)
WO (1) WO2015048145A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192899A1 (en) * 2021-03-11 2022-09-15 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance
JP2024532810A (ja) * 2021-08-13 2024-09-10 ラピックス セラピューティクス， インコーポレイテッド 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
CN117940407A (zh) 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法
EP4608969A1 (en) 2022-10-25 2025-09-03 Lapix Therapeutics, Inc. Immune cell-engrafted non-human animals and non-human animal models
WO2024118602A1 (en) 2022-11-29 2024-06-06 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625584B2 (en) 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
WO2007117469A2 (en) 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US20120164189A1 (en) * 2009-07-07 2012-06-28 Balu-Iyer Sathy V Lipidic Compositions for Induction of Immune Tolerance

Also Published As

Publication number Publication date
JP2016531853A (ja) 2016-10-13
CN105992591A (zh) 2016-10-05
WO2015048145A1 (en) 2015-04-02
EP3049103A1 (en) 2016-08-03
EP3049103A4 (en) 2017-09-27
EP3049103B1 (en) 2020-06-24
WO2015048145A9 (en) 2015-06-25
ES2807550T3 (es) 2021-02-23
US20160243220A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
US20250319075A1 (en) Phosphoserine containing compositions for immune tolerance induction
US20200046816A1 (en) Compositions and Methods for Antigen-Specific Tolerance
JP6783652B2 (ja) 抗原特異的免疫原性を低減するための組成物及び方法
US20120164189A1 (en) Lipidic Compositions for Induction of Immune Tolerance
Cruz-Leal et al. The vacuolar pathway in macrophages plays a major role in antigen cross-presentation induced by the pore-forming protein sticholysin II encapsulated into liposomes
JP2022101576A (ja) スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
TW201039843A (en) Compositions and methods for induced tolerance
CN114302741A (zh) 用于治疗自身免疫性疾患的组合物和方法
Glassman et al. Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher
JP2024069198A (ja) 活性剤及び免疫調節剤のリンパ節への標的化送達のための方法及び組成物
JP2014040438A (ja) アテローム性動脈硬化の治療
US11701328B2 (en) Phosphoserine containing compositions for immune tolerance induction
Ramakrishnan et al. Effect of biophysical properties of phosphatidylserine particle on immune tolerance induction toward factor VIII in a hemophilia A mouse model
Fathallah et al. O‐Phospho‐l‐Serine mediates Hyporesponsiveness toward FVIII in hemophilia a‐murine model by inducing tolerogenic properties in dendritic cells
US20220016241A1 (en) Compositions and methods for reducing antigen-specific immunogenicity
JP2020183446A (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
US20250387461A1 (en) Compositions and methods for antigen-specific tolerance
WO2025257777A1 (en) Materials and methods for improved three-dimensional immunity
Glassman Phosphatidylserine-based Nanoparticles for Tolerance Induction Towards Therapeutic Proteins
Ramakrishnan et al. Oral Immune tolerance induction to Factor VIII using Phosphatidylserine liposomes
Balasubramanian Effect of biophysical properties of Phosphatidylserine (PS) particle on immune tolerance induction towards Factor VIII in a Hemophilia A mouse model
Fathallah Addressing immunogenicity and pharmacokinetic issues associated with subcutaneous administration of protein therapeutics
Guan Development of liposomal antigen delivery system for synthetic MUC1 peptides.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190619

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201022

R150 Certificate of patent or registration of utility model

Ref document number: 6783652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250